The mechanisms of COVID-19-induced increased triglyceride (TG) levels are not fully understood but are hypothesized to be related to hemophagocytic lymphohistiocytosis (HLH) syndrome, acquired lipoprotein lipase (LPL) inhibitors, liver failure, or as a side effect of medications [3]. The gene discussed is LPL; the disease is liver failure.